Cargando…
Lower starting dose of roxadustat in non-dialysis-dependent chronic kidney disease patients with anaemia: a study protocol for a randomised, multicentre, open-label study
INTRODUCTION: Roxadustat is a first-in-class oral therapy that treats chronic kidney disease (CKD) anaemia with the benefit of a novel mechanism of action that consistently corrects and maintains haemoglobin (Hb) across the spectrum of non-dialysis-dependent (NDD) CKD anaemia with an acceptable safe...
Autores principales: | Li, Ping, Sun, Xuefeng, Chen, Dinghua, Lin, Hong-li, Zhang, Li, Wu, Yiqing, Pan, Shuting, Cai, Guangyan, Chen, Xiangmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923260/ https://www.ncbi.nlm.nih.gov/pubmed/36759031 http://dx.doi.org/10.1136/bmjopen-2022-068864 |
Ejemplares similares
-
Exploring experiences and health-related quality of life of caregivers of patients who start home dialysis: study protocol for a prospective, multicentre cohort study
por: van Lieshout, TS, et al.
Publicado: (2022) -
Efficacy of roxadustat in treatment of peritoneal dialysis patients with renal anaemia
por: Zhu, Xin-Wang, et al.
Publicado: (2021) -
Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies
por: Akizawa, Tadao, et al.
Publicado: (2019) -
Complications and outcomes of urgent-start peritoneal dialysis in elderly patients with end-stage renal disease in China: a retrospective cohort study
por: Zang, Xiujuan, et al.
Publicado: (2020) -
Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies
por: Yamamoto, Hiroyasu, et al.
Publicado: (2019)